Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of In-Vitro Chemotherapy Effectiveness Tests for Cancer Patients
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar…
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving…
deCODE genetics: Complete recombination map of the human-genome, a major step in genetics
REYKJAVIK, Iceland, Jan. 22, 2025 /PRNewswire/ -- Scientists at deCODE genetics/Amgen have constructed…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…
Myriad Genetics RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.…
SOPHiA GENETICS Launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024
Launch of new application enables global access to highly recognized solid tumor…
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illuminas Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a…